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Quality control (QC) results are used to validate 
whether the instrument is functioning within pre-
defined specifications, deducing that patient test 
results are correct and reliable. Once the test system 
is validated, patient results can then be used for 
diagnosis, prognosis, or treatment planning. The data 
obtained from the daily analysis of QC pools can be 
plotted to create a visual analysis also known as the 
Levey-Jennings or LJ chart. The expected analyte 
concentration, the established target value (mean), 
and the desired number of standard deviations are 
drawn on the y-axis, and the days of the month 
are drawn on x-axis. Lines run across the graph at 
the mean, as well as one, two and sometimes three 
standard deviations either side of the mean. This 
makes it easy to see how far off the result was. 
In 1981, Dr. James Westgard and his associates 
developed a multi-rule procedure for interpreting control 
data. In short the Westgard rules specify the LJ chart. 
These rules are QC rules to help analyze whether or not 
an analytical run is in-control or out-of-control. Any 
values violating Westgard rules will be either rerun or 
rejected depending on the rule violated. There are six 
basic rules in the Westgard scheme. These rules are used 
individually or in combination to evaluate the quality 
of analytical runs. It makes use of a series of control 
rules for interpreting control data and also reduces 
the false rejection and improves the error detection. 
The formulation of Westgard rules were based on 
statistical methods. They are also used to define specific 
performance limits for a particular assay and can be used 
to detect both random and systematic errors.
Levey Jennings Chart and Guide to use 
Westgard Rules
From the Editor’s Desk
Dr Syed Bilal Hashmi
Clinical Chemistry
This is the last issue of 2017 and we enter the 
New Year with a very well suited thematic 
issue on “Quality Assurance in Laboratory”. 
Accredited laboratories follow a highly stringent 
compliance criterion of regulatory laboratory 
standards, quality assurance systems, validation 
protocol for diagnostic tests along with support of 
highly effective laboratory information system to 
guarantee quality of standards and reliability of 
analytical data.
Successful quality assurance programmes provide 
consistent test results with minimal chances of 
error and being a College of American Pathologists 
(CAP) certified laboratory we are constantly 
striving to provide this to our end users. With this 
background, the current issue contains articles on 
quality assurance being practiced in all sections 
of the laboratory. The topics include: guide to use 
Levy Jennings chart, quality assurance in frozen 
sections, quality assurance in laboratory biosafety 
and quality requirements for reporting sickling 
haemoglobin to name a few. We also have the 
pathology and radiology correlation article which 
has become a favorite by the readers.
We hope our readers enjoy the material as much as 
we enjoyed putting it together…
Happy New Year 2018!
Rule 
12s
13s
22s
R4s
41s
10x
Interpretation 
One control measurement exceeds  ± 2SD limits
One control measurement exceeds  ± 3SD limits
Two consecutive control measurements exceed  ± 2SD limit
If there is at least a 4SD difference between control values within a single run
4th consecutive control measurement exceeding 1SD on the same side of the mean
When there are 10 consecutive controls on the same side of mean
Type of Error 
Warning
Random
Systematic
Random
Systematic
Systematic
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Quality Assurance in Frozen Section Studies
Dr Arsalan Ahmed and Summayia Sohail
Histopathology 
Correlation of Intraoperative and Final Diagnosis
Monitoring the correlation of frozen section 
diagnosis and permanent section diagnosis is an 
integral component of a quality assurance/quality 
improvement program in histopathology. It provides 
a very important measure of performance with 
respect to frozen section diagnostic accuracy. It 
is recommended that permanent section slides 
should be analyzed with the accompanying frozen 
section slides to establish if any discrepancy exists 
(CAP checklist item ANP.10075). Each frozen 
section disagreement (major) should be treated 
as an event that requires investigation and action, 
and discrepancies should be reconciled in the final 
pathology report (CAP checklist item ANP.10100). 
Local protocols should outline the process for 
treatment of a major discordance. 
The Association of Directors of Anatomic and 
Surgical Pathology (ADASP) have recommended the 
following correlation categories.
l Concordance
l Deferral-Appropriate
l Deferral-Inappropriate
l Disagreement-Minor
l Disagreement-Major
Correlation Results
l Concordance – represents cases where frozen  
 section and permanent section diagnosis are in  
 agreement           
l Deferral rate - The number of cases where   
 frozen section diagnosis was deferred until final 
 diagnosis was reached on permanent section
l Minor Disagreement/Discordance – represents 
 a small change in diagnosis but there is minimal, 
 if any, clinical relevance
l Major Disagreement/Discordance – represents 
 a significant difference between the original 
 frozen section diagnosis and the one rendered 
 upon final diagnosis where potentially there is a 
 serious impact on the patient’s treatment or outcome.
Reasons for discordance and their reported relative 
frequencies include:
	 l Misinterpretation 25% to 45%
	 l Specimen sampling    30% to 45%  
	 l Block Sampling        30% to 38%
	 l Technical inadequacy 30% to 38%
	 l Inadequate clinical data  6% to 8%  
	 l Labeling errors                      0.5% to 3%
A number of variables must be considered 
when collecting and interpretating quality 
assurance data on frozen section performance 
as follows:
l Differences in case mix potentially can account 
 for difference in diagnostic accuracy of frozen 
 section. It is recognized that certain frozen 
 section activities (e.g. Sentinel lymph node, 
 assessment of surgical margins) have a high 
 discordance rate.
l Performance data will depend upon whether case 
 discordance (# discordance/ # frozen section  
 cases.) is calculated, or whether the number of 
 blocks (# discordance/ # of all individual frozen 
 sections) is utilized in the denominator.
l Calculations of discordance can be based on 
 broad comparison of benign versus malignant or 
 more specific diagnostic terminology.
ADASP recommends an acceptable accuracy 
threshold of three percent for intraoperative 
consultation. In every month the data is recorded 
as a quality indicator and the frequency of 
discordance compare with its bench mark and 
presented in sectional meeting and DQMC 
(Departmental Quality and Mangagement 
Committee).
Turnaround Time
Frozen section TAT has a critical impact on operative 
management. The turnaround time target is 20 
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minutes or less for single frozen section specimen, 
measured from the time that the pathologist 
receives a frozen section specimen to the time 
that a diagnosis is reported to the surgeon .More 
than 20 minutes is acceptable in cases where 
more than one block is processed or more than 
one specimen is received for the same patient. 
Frozen section record is kept in the quality 
indicator. The laboratory should be able to meet 
the 20 minute time limit for at least 90 percent of 
cases.
Monthly Evaluation of Frozen TAT
The monthly evaluation of frozen TAT is monitored 
and recorded. The list is presented and discussed in 
the departmental sectional meeting.This data is also 
shown in DQMC meeting.
Turnaround Time
Turnaround time is the basic performance 
improvement monitor throughout anatomic 
pathology. The basic approach that can be used 
to track TAT in histology, is to use specific time 
“stamp” through the laboratory information system. 
This approach requires an entry at the time, tissue 
blocks are submitted or a special request is made, 
and an entry when the slides are released from the 
laboratory. With this approach, the actual TAT in 
hours can be specifically determined and trended.
Quality of Histologic Sections
The quality of histologic sections would be 
assessed by the pathologist receiving histologic 
preparations.  The supervisor and technologists 
must work together to ensure that pathologist input 
is meaningful and consistent. A quality assessment 
form is designed and the pathologists are instructed 
to indicate a specific problem using coded 
comments and individual case numbers. This form 
assists the histology laboratory in documenting 
corrective action, in compiling summary reports by 
defects and in detecting trends.
Lost Specimen
A lost specimen is defined as “the loss of surgical 
pathology specimen that has occurred after the case 
has been accessioned in the laboratory and that 
prevents an adequate pathologist examination of that 
specimen. The acceptable threshold for these events 
was defined by ADASP as one in 3000 cases.
A tissue lost may occur at the time of grossing, at 
the time of processing due to failure of completely 
close cassettes, or loss of tissue blocks. Every effort 
should be made to find or account for “lost” surgical 
pathology specimens. The staff member discovering 
the discrepancy will immediately inform to the 
supervisor of Histology who in turn should notify 
the pathologist and the incident is considered as a 
non-conforming event and is documented on a lab 
non- conforming event form.
Floaters
Floaters are the small piece of tissue that arises from 
a source other than the case under examination. 
Floaters mainly arise due to cross contamination 
during grossing, embedding, Microtomy or staining. 
Identification of floaters by the pathologist can be 
tracked using the form or marked on a slide and 
number of occurrences per total tissue blocks or 
slides can be aggregated as a useful performance 
improvement monitors.
The average rate of occurrence on prospective slide 
review for participants in Q-probe studies were 
0.6 percent of slides, 0.8 percent of blocks and 1.2 
percent of specimen. Following steps can be taken to 
reduce its frequency.
l All instruments used in grossing e.g. forceps,  
Performance Improvement Monitors in 
Histology
Dr Arsalan Ahmed and Summayia Sohail
Histopathology 
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 scalpels and scissors should be cleaned after  
 every case.
l Floatation bath at microtome stations should be 
 frequently cleaned, particularly following any 
 poorly processed tissue that explodes on the 
 water bath.
l Embedding forceps must be carefully cleaned off 
 paraffin after every case.
Histology laboratories must provide high quality 
services by enforcing a technical quality control 
Accreditation bodies around the globe encourage 
assays harmonization to not only improve quality 
of care but also improve efficiency, patient 
satisfaction, and overall clinical operations. As 
numbers of clinical laboratories are expanding it 
is becoming more important that test performed 
by different laboratories are standardized. Patients 
receiving care across a healthcare network expect 
uniform laboratory services throughout and any 
differences in results reported from two sites or 
laboratories can create confusion for patients 
and clinicians. For example, serum creatinine 
performed at two different labs on a specific 
sample should give similar results (within analytes 
specific allowable error). In instances where 
assays are not standardized due to non-availability 
of primary reference materials, guidelines 
recommend that the follow up should be done with 
a single method and baseline be re-determined, 
when assay or methodology is changed. 
Method standardization directly affects result 
accuracy which in turn affects patient’s outcome. 
Ideally all methods should be completely 
comparable, but that is not noted in practice and 
intermethod differences can affect the clinical 
decision making. In long term monitoring a 
patient can change or switch hospital or the 
laboratory which has a different method of 
analysis for that specific analyte. Clinicians 
need testing standardization to interpret results 
system. This can only be achieved by providing 
accurate, relevant, precise and comprehensive data, 
which is applied to medical management of patients. 
Any misdiagnosis or errors on reports can lead to 
massive impacts on the quality of service and health 
consequences to patients. Thus, laboratories must 
follow quality rules and standards that are already 
established. More so, the goal of quality management 
in laboratories should be to ensure continuous 
improvement which would guarantee quality service 
and quality laboratory results to consumers.
properly. Seeing different results can be very 
confusing to clinicians and can potentially 
results in misinterpretation of laboratory results. 
For example when multiple laboratories in a 
country offer different cTn assays (I versus T 
and new high-sensitivity versus contemporary), 
misdiagnosis is a distinct possibility. Patient 
diagnosed based on cTn-T assay cannot be 
monitored with cTn-I assay. 
Pathologists also face difficulties in interpreting 
reports of samples sent to reference laboratories 
for comparison when difference in methodology 
exists. Two non-standardized assays can produce 
different results. In such instances deriving 
qualitative or concordance for comparison will be 
helpful. Taking fecal calprotectin as an example 
for non-standardized assay; a patient with 
inflammatory bowel disease will have raised fecal 
calprotectin performed by two different methods 
with good concordance but the bias between 
results of the two methods can be high.  
The main aim of clinical laboratories is to 
provide information that is useful to help medical 
decision-making, allowing optimal patient health 
care.  The standardization of laboratory results 
assuring interchangeability of results would 
significantly contribute to improvements in health 
care, since lab results performed in different 
locations or times could be universally applied.
Assay Standardization and Challenges Faced 
by Laboratories
Dr Hafsa Majid
Clinical Chemistry
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During grossing, the specimen is visually examined 
for suspicious areas which need to be sampled for 
microscopic examination. In order to achieve optimal 
and reproducible immunohistochemical staining, thin 
tissue sections (usually less than 3mm in thickness; 
and 2 x 2 cm in size) are submitted for processing 
and cutting. During these processes, rigorous checks 
are kept on the system to detect any fault that may 
render the tissue block unsuitable for microscopic 
examination and subsequent immunohistochemical 
testing.
Analytic steps: Staining is the analytical part of 
the immunohistochemical process. It encompasses 
antigen retrieval (to recover tissue antigens that 
may have been altered by improper fixation); 
blocking of endogenous enzymes; application 
of the primary antibody (that may or may not be 
followed by application of secondary antibody); 
use of chromogen to visualize antigen/antibody 
complex; and visualization system, ending with 
counterstaining. In our laboratory, all these 
processes are performed on state of the art DAKO® 
autostainers using DAKO EnVision® Kits.
Post-analytic steps: In post analytic phase, the 
pathologist interprets the stains in context with 
positive and negative tissue controls using bright 
field microscopy. The observed results are analyzed 
in conjunction with the light microscopic features 
of the tumor and are then incorporated into the final 
histopathology report. 
Routine Quality Control; Use of Daily Controls 
and Interpretations of Immunostains 
The single best evidence that the antigen has been 
adequately demonstrated in a particular tissue is to 
look at the internal control. Internal control refers to 
antigens present in the normal tissue structures of the 
patient tissue being tested.  Unfortunately, an internal 
control may not always be present. To overcome 
this issue, with each batch of immunohistochemical 
stains that we run in our laboratory a set of positive 
and negative tissue controls for a particular antibody 
Quality Assurance in Immunohistochemistry: 
The Way We Do It
Dr Sabeehuddin Siddique and Dr Khurram Minhas
Histopathology
Introduction
Immunohistochemistry (IHC) is a method for 
localizing specific antigens in tissue or cells based 
on antigen-antibody recognition. It has become an 
indispensible tool in today’s practice of surgical 
pathology. The Histopathology section at Aga Khan 
University Hospital Karachi has pioneered the use of 
immunohistochemical stains in laboratory practice in 
Pakistan and with the passage of time the number of 
procured antibodies is increasing. On the other hand, 
the accrediting agencies for clinical laboratories, 
such as College of American Pathologists have 
laid down stringent policies and guidelines for 
standardization, quality assurance, quality control 
and improvement of immunohistochemistry 
techniques.
Steps in Immunohistochemical Testing
The factors affecting the quality of results in 
immunohistochemistry include events spanning from 
the identification of the specimen to interpretation 
of the stain and then its assimilation into the final 
report. But before delving deeper into the details of 
quality assurance process in immunohistochemistry, 
and the way we achieve it in our laboratory, it 
is imperative to have a basic idea about how the 
process of immunohistochemical staining works. 
This entire process can be broadly divided into pre-
analytic, analytic and post-analytic phases. 
Pre-analytic steps: In order to reduce the ischemic 
time until fixation, the specimen should be 
immediately immersed in a standardized fixative 
(such as formalin) as soon as it is surgically removed. 
Therefore, upon being received in the laboratory and 
after accessioning, all the specimens are specifically 
checked if they have been adequately placed in 
formalin. Specimens received in other medium 
are transferred into formalin to prevent further 
autolytic changes. Use of non-formalin fixatives is 
strongly discouraged, and there are only a handful of 
exceptions to its use including Bouin’s solution for 
testicular biopsies and Zenker’s solution for lymph 
nodes. 
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are also applied. The stains, along with the respective 
positive and negative tissue controls, are reviewed 
by an experienced histopathologist before being 
distributed. Any discrepancy observed is logged, 
notified to other pathologists and corrective measures 
are taken. In fact, the process of daily quality 
control does not end here. After the distribution of 
stains, each signing out consultant interprets the 
immunohistochemical staining in conjunction with 
the provided controls and in context with tumor 
morphology. Table 1 highlights the key parameters 
that may adversely affect the immunohistochemical 
staining quality.
Evaluation and Validation of new Antibody 
Whenever a new antibody is introduced in our center, 
it is diligently evaluated, optimized and validated 
before being used for diagnostic purpose. The goal 
of this process is to establish the optimal titration, 
detection system and antigen retrieval protocol. 
Once the antibody has been optimized, it is tested on 
laboratory tissue in order to determine the sensitivity 
and specificity. Simple it may sound; this process 
can be quite cumbersome, especially if the optimal 
dilution titer is not achieved even on repeated 
attempts.
Validation of new Lot 
Each new lot of antibody must be validated 
before it is used in clinical assays. For an 
established primary antibody that is performing 
well, the laboratory need only stain a small 
series of tissues, including the routine 
positive and negative controls. For new lots 
of detection system reagents, a similar side-
by side comparison of the old and new lots 
should be performed and recorded using series 
of monoclonal and polyclonal antibodies that 
optimally test the specificity and sensitivity of 
the detection system. 
External Quality Assessments; Participation in 
Cap Survey Program 
Besides having a stringent internal quality 
assessment tools, Aga Khan Hospital Clinical 
laboratories has also been participating in the 
external quality assessment programs offered by 
the College of American Pathologists. One such 
program is The MK program of the American 
College of Pathologists in which unstained tissue 
sections are provided to our laboratory along with a 
clinical history and specifications as to which stains 
should be performed. After performing the relevant 
immunihistochemical 
stains, a Consultant 
histopathologist records 
the stain results and 
a favoured diagnostic 
interpretation based on 
history, the histologic 
appearance and the 
immunophenotype. 
These results are 
shared with the college, 
which then sends a 
summary report that 
includes the interpretation of the referees as well as 
statistics on the response of participants, stratified 
by antibody preparation used. These materials 
provide an excellent mechanism of external quality 
assurance and a source of published benchmarks for 
reproducibility.
Quality Assurance Monitors
Besides continuous monitoring of the 
immunohistochemical staining processes, it is crucial 
that the laboratory keeps track and record of various 
quality indicators pertaining to this process. Our 
laboratory is no exception to this rule. We not only 
periodically review the data inferred from these 
records but are bound to share this information with 
the College of American Pathologists as a part of 
our accreditation process. A few noteworthy of such 
parameters are listed below.
 1. Repeat Slides: An inadequate 
  immunohistochemical stain may be the result of 
  less than optimal tissue selection and/or 
  processing, antibody failure or technical 
  failure. It is important for the laboratory to 
  document all requests for repeat stains, 
  the reason for the request, the corrective action 
  performed and the final outcome. Interaction 
  of the pathologist and technologist on a 
Table 1: Key parameters that may have an adverse effect on staining quality
Monitor
Temperature of processors, embedding 
centers and slide drying apparatus
pH of antigen retrieval solution
Temperature of antigen retrieval solution/
chamber
Checklist for automated instrument set-up
Reagent expiration dates
Potential Adverse Effect
Antigen degradation due to excessive heat
Decreased immunoreactivity due to incorrect pH
Failure to reach the optimal temperature
Selection of incorrect protocol or failure to apply correct
reagents results in absence of desired immunoreactivity
Use of reagents beyond the manufacturer’s expiration 
date may result in inconsistent staining
9VOL. 43, ISSUE 3DECEMBER 2017
Quality Assurance in Laboratory Biosafety
Syeda Kiran Zaidi
Clinical Microbiology
Laboratory safety is a vital part of total quality 
assurance program of our laboratory. “Quality 
assurance” is all the policies and systematic 
activities implemented within a quality system and, 
“Biosafety” is application of knowledge, techniques 
and equipment to prevent personal, laboratory and 
environmental exposure to potential infectious agents 
or biohazards. Together, we can say Biosafety is all 
the actions taken to improve the quality of work and 
personal safety.
Risk Assessment
The backbone of the practice of biosafety is risk 
assessment. While there are many tools available to 
assist in the assessment of risk for a given procedure 
or experiment, the most important component is 
professional judgment. Risk assessments should 
be performed by the individuals most familiar with 
the specific characteristics of the organisms being 
considered for use, the equipment and procedures 
to be employed, and the containment equipment 
and facilities available. Most healthcare workers are 
familiar with biosafety levels we are working in.
Policies and Standards
Every institute must have a safety policy which 
should include: 
1.  A reporting hierarchy for 
 safety officers designated 
 to each area for  monitoring  
 safety indicators
2. Reporting any incident 
 with a breach in biosafety
3. Regular audits of the 
 facility to inspect for safety 
 of the working environment
  case-by-case basis is essential for successful  
  troubleshooting.
 2. Turnaround Time: Immunohistochemistry may 
  add significantly to the overall turnaround time 
  of surgical pathology or cytopathology case. As 
  these may be high profile cases, objective 
  monitoring of turnaround time, either 
  periodically through a retrospective audit or 
  prospectively through the routine use of time 
  stamps, is a useful quality assurance measure.
 3. Audits of Pathology Reports: A retrospective 
  review of reports from cases utilizing 
  immunohistochemistry stains may provide 
  very useful information on the efficacy and 
  efficiency of ordering practices by the 
  pathologists as a group and individually. More 
  importantly, a review by a pathologist not 
  involved in the case can provide useful 
  feedback regarding the clarity and completeness 
  of reporting. 
Besides the aforementioned quality assurance, 
management and regulation processes in 
immunohistochemistry followed in our 
laboratory, additional requirements have 
been laid down by the College of American 
Pathologists, for reporting the results of 
predictive marker studies for breast cancer 
(including ER, PR and Her2-neu. We strictly 
adhere to these policies in order to produce 
the optimal staining results, as it has major 
implications in the management of disease. 
Quality Assurance Cycle - Medical Laboratory
Image courtesy: Google Images Image courtesy: Google Images
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Policies provide a recommendation to uphold 
the standards set by the institute as per EPA 
(Environmental Protection Agency) Regulations, 
Federal, Provincial and Local Regulations, Joint 
Commission International and College of American 
Pathologist Standards are also included. Laboratory 
safety standards must include 
	 l A chemical hygiene plan which covers all 
  the hazardous materials used in the section. 
  The Material safety data sheet (MSDS) 
  should list and give details of all chemicals 
  used in each department. Each employee 
  should be well-versed in responding to 
  biological and chemical spills, and use of 
  spill kits. Eye wash stations are checked 
  daily and on monthly basis to ensure proper 
  working
	 l Blood borne pathogen standard which 
  includes universal precaution (Discussed 
  below) and vaccination and post-exposure 
  prophylaxis.  
	 l Personal hygiene especially hand washing 
  and keeping work garments free of 
  biohazard. 
	 l Disposal of used linen and hospital garments 
  for both patients and staff
	 l Disposal of sharps and biohazardous wastes 
  in appropriate containers and incineration or 
  deep burial
Any safety issues should be discussed in meetings 
held on regular basis. Moreover, monthly indicators 
are also sent to the chief safety officer for review. 
Knowledge of safe practices can be enhanced through 
planned lectures and drills. Each employee working in 
the laboratory must be aware of firefighting, location 
and usage of fire extinguishers, fire alarms, and fire 
rescue team numbers. There should be designated 
assembly areas in case of fire or earthquake for the 
workers of all departments to facilitate headcount. 
Infection Control
Infectious diseases are a major risk to patients, 
visitors and staff. Infectious diseases can be spread 
through direct contact or the air. 
	 l Blood borne pathogens include Hepatitis 
  B Virus (HBV), Hepatitis C Virus (HCV) 
  and Human Immunodeficiency Virus 
  (HIV). Exposure to a Blood-borne pathogen 
  is a risk for faculty and staff of health-care 
  facilities. Health Care Workers in hospital 
  setting are at high risk of acquiring Hepatitis 
  B viral infections. So immunizations are 
  offered to all employees at risk of these. A 
  full course of Hepatitis B vaccination 
  consists of three (03) injections at zero, one 
  and six months. All these three doses are 
  compulsory for the safety of employees.
Universal Precautions:
 1. Follow Standard (Universal) Precautions: 
  Blood and body fluid from all patients must 
  be handled as if they were infected with a 
  Blood borne pathogen.
 2. Wash hands: after removing personal 
  protective attire, before leaving the restroom, 
  after contact with blood/body fluids or after 
  handling contaminated items, before and 
  after eating
	 	 l Proper method for washing hands: 
  Using regular soap, running water, rub hands 
  10-15 seconds of friction. After rinsing, dry 
  hands and then turn off the faucet with the 
  paper towel. 
 3. Personal protective equipment: Wear gloves 
  when expecting to
	 	 l Touch items or surfaces contaminated 
   with blood or other body fluids.
	 	 l Handle blood or other body fluids specimens.
	 	 l Come in contact with patient’s open skin 
   lesions.
	 	 l Obtaining a blood sample.
Always wash hands after removing gloves. Wear 
a face shield or a combination of a facemask and 
protective eyewear when at risk of splash or spray 
to the face. Apron or other barrier gown can protect 
personal clothing when it is likely to become soiled 
due to splashes; if penetrated by blood or body fluid, 
remove it as soon as possible. 
 4. Needle stick injuries (NSI)/sharps injury/
  mucosal exposures to blood and body fluids 
  are hazardous to your health. If injured, put 
  the area under running water until it stops 
  bleeding. Wash the site with soap and water, 
  dry and cover with bandage. Trace patient’s 
  HIV, HBV, HCV status and notify the safety officer. 
Image courtesy: Google Images
4 5 6 7Rub your nails andyour palm Rub the back of the handand between fingers Rinse hands with clean water Dry hands with cleancloth or tissue
1 Wet your hands andapply soap throughly
Proper
handwashing
techniques
2 Rub both of yourpalms together 3 Rub each fingers andbetween fingers
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Quality Control of Culture Media Used in 
Clinical Microbiology
Sobia Noshad Baig
Clinical Microbiology
Culture media plays an essential role in the 
clinical microbiology laboratory. The isolation of 
microorganism is the prerequisite for identification 
and sensitivity of pathogenic and nonpathogenic 
organisms.  Most laboratories prepare their 
own culture media for routine diagnosis and for 
research purpose. For ensuring the culture media’s 
quality, quality control strains and materials are 
set simultaneously to assess the complete range of 
purpose for which the media is used. The batch of 
media agar and broth prepared is thus considered fit 
for use only after passing through rigorous quality 
checks.   
Raw Material
The quality of the culture media depends directly 
upon the quality of the raw materials used for 
preparation. 
Only distilled water is used for the preparation of 
cultural media. The water pH should be monitored 
daily, and should be slightly acidic to neutral but 
no lower than 5.5, as highly acidic pH may inhibit 
the growth of microorganisms.The petri dishes used 
for pouring of culture media should be ethylene 
oxide (EtO) sterilized or gamma irradiated. Only 
borosilicate glassware should be used because soda 
glass can leach alkali into the media and change 
its characteristics. There are various supplements 
used in preparation of culture media including 
supplements for enrichment, e.g. blood, NAD, 
hemin and certain vitamins, and other inhibitory 
additives, like antibacterial and antifungal agents 
etc. Traditionally, animal blood should be used e.g. 
sheep or horse, in most blood containing media, but 
human blood has also been used with acceptable 
results. Blood is collected aseptically and inoculated 
in agar media after cooling to 50oC so that it doesn’t 
denature. For additives purchased as prepared 
supplements, the certificate of analysis and sterility 
and temperature at the time of addition are important 
considerations.
Sterilization
Sterilization plays an important role in the quality 
of the culture media. Generally, for media with heat 
stable components, autoclave is used for sterilizing 
the culture media. However, the time of autoclaving 
and the quantity of culture media sterilized should 
be closely regulated. The standard autoclaving cycle 
is maintained at temperature 121°C for 15 minutes 
and 15 psi pressure. Overheating of bacterial media 
can cause nutrient destruction, so temperature and 
pressure timings are very important.
The volume of the bacterial media in sterilization 
batch should be kept small, ideally two liters. 
Sterilization process indicators should be checked 
regularly. Temperature and pressure should also be 
plotted while the autoclave is running so that it can 
be monitored live. Records of biological indicators 
(e.g. spore strip or bromthymol purple broth with 
Geobacillus stearothermophilus spores) and chemical 
and steam penetration indicator (e.g. Bowie Dick 
The reporting of culturable 
microorganisms, bacteria or 
fungus, depends upon the quality 
and sterility of the cultural media. 
The quality and quantity of media 
directly affects the observations 
and results. Different parameters 
of media such as poor growth 
support, physical characteristics 
and batch contamination can 
result in false reporting. The 
less quantity of media agar or 
supplements also results in poor 
growth. There are different 
methods of checking all these 
parameters systematically.
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test) to check the efficiency of the process must be 
maintained.
Physical appearance
The gross physical appearance of bacterial media 
often shows the quality of media pouring. Prepared 
bacterial media should be screened for physical 
characteristics such as excessive bubbles or pits, 
unequal filling of plates (non-uniform levels), 
thickness of medium in the plate, which must be 4.0 
± 0.2 mm, cracked and frozen or crystallized medium 
in plate.
All the above 
mentioned 
characters can be 
checked visually 
by naked eye. 
The pH of the medium is also an extremely 
important physical characteristic, which must be 
checked. It can be measured after autoclaving of 
media by using the standard pH meter after proper 
calibration with standard buffers.
Microbiological parameters
Growth support is the most important parameter 
while conducting quality control of media. Standard 
inoculating procedures should be used, it includes 
positive control and negative control. National 
Committee for Clinical Laboratory Standards 
(NCCLS) has laid down certain guidelines for the 
control organisms to be used for every medium, the 
desired inoculum concentration and their expected 
growth results. After inoculation, the plates are 
incubated at 37°C for 24 hours and their growth 
and colony characteristics are observed. The results 
can be reported by mentioning presence or absence 
of growth and the growth characteristics. The 
results should be examined both qualitatively and 
quantitatively. While testing new lots, both previous 
batch and new batch should be simultaneously 
inoculated.
Contamination 
This is a crucial parameter for the determination of 
the quality of media. The batch must be checked for 
contamination before passing for laboratory use. It is 
also suggested that the whole batch of the prepared 
media be checked for contamination by keeping the 
plates at least for three days at room temperature in 
case of a small batch (<100 plates). Alternatively, 
5-10% of plates from the test batch can be taken and 
placed into the incubator set at 37°C for 24 hours. 
After required incubation, the plates are checked 
for any growth. If there is any growth, the sterility 
of the batch is rechecked, taking double the number 
of plates from the same batch. If contamination is 
confirmed in more than 10% of the incubated plates 
from the batch, the media must be discarded, as per 
recommendations.
EZ TEST (Biological indicator):  
Bromthymol purple broth with
Geobacillus stearothermophilus spores.
VIOLET (Sterilized), YELLOW (Unsterilized)
BOWIE DICK STRIPS DARK BROWN – lower 
strip (Poor steam penetration), BLACK- upper strip 
(Good Steam penetration)
Excessive bubbles in media.
Cracked media.
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Conclusion
The quality control (QC) of bacterial media used in 
clinical microbiology laboratory remains critical for 
accurate and acceptable isolation of pathogens from 
infected patients. Reference strains must be used as to 
assess whether the media is behaving as expected for 
both bacterial isolation, identification and sensitivity 
testing, before releasing the batch for use in the 
laboratory. Testing media using standard protocol can 
save time and resources and ensure reliable reporting. 
Contaminated culture plates
Quality Assurance is a way to achieve quality 
service. In the clinical diagnostic laboratory it 
ensures that laboratory processes are controlled 
at every stage and the results generated by the 
laboratory are accurate, reliable, timely and 
reproducible. 
Infectious diseases serology is an important diagnostic 
modality because it provides analysis of disease 
without any invasive intervention with a limited span 
of time. These tests are qualitative semi-quantitative 
and quantitative. For better and accurate result 
interpretations, vigilant test procedure is required. 
However, the laboratories especially in resource 
limited countries have questionable reliability of 
infectious serology results due to noncompliance with 
the quality procedure and practices.  Use of unreliable 
diagnostic kits without performing proper quality 
assurance is one of the major limiting factors for 
reproducing good quality report. 
Components of Quality Assurance
Pre-analytical:
 1. Sample collection: 
  Sample must be collected in assigned 
  appropriate tube/container and should be 
  rejected if received in wrong container or 
  wrong labeling. 
 2. Sample transportation: 
  Recommended condition for sample 
  transportation must be followed like 
  maintaining temperature and adding 
  preservative if there is any delay in 
  transportation.
 3. Sample processing: 
  Before performing the quality of specimen 
  must be assessed visually (Hemolysed, 
  lipemic or turbid sample). 
  The test sample must be processed according 
  to kit manufacturer’s instruction. 
Analytical:
 1. Method validation
  Before starting to use any diagnostic kit, 
  the following important points must be taken 
  into consideration by the users. 
 l Use those kits whose manufacturer is well 
  known and reliable in diagnostic products.
	 l Diagnostic kit should be approved by some 
  reliable international quality assurance 
  agencies. (FDA or CE marked)
	 l Do not use kits which are intended for 
  research purposes only. 
	 l Ensure thorough literature review and 
  market search before selecting any kit. 
  Laboratories can select those manufacturers 
  whose kit is in use by majority of peers if 
  you are a participant of a Proficiency testing 
  program (e.g. Proficiency testing by College 
  of American Pathologist -CAP).
Once selection has been done and kits received in 
the laboratory, following quality assurance (QA) 
Quality Assurance (QA) in Qualitative Tests in 
the Clinical Laboratory
Najma Shaheen
Clinical Microbiology
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parameters must be performed as a validation and 
verification process. Validation process must be 
repeated if there is a change in methodology or 
manufacturer. 
 a. Sample selection: To validate a diagnostic 
  kit known positive and negative samples are 
  required. Proficiency test samples (CAP 
  surveys) can be used for this purpose. 
  Well characterized positive clinical samples, 
  having relevant clinical history of that 
  disease and rechecked with authentic 
  methodology by some other laboratory with 
  better quality assurance process can also be 
  used. 
 b. Number of samples required: 10-20 
  positive and 10-20 negative samples or well 
  characterized samples is the minimum 
  requirement for verification process of FDA 
  approved tests. For non-FDA approved or 
  modified FDA approved tests, the sample 
  size is much larger, comprising 100-150 data points.
 c. Accuracy: this parameter tells us that how 
  much our method is accurate to generate 
  the result, if we are running a sample of 
  known concentration. It is calculated by:
   Accuracy=No. of correct results/ total 
   no. of results x 100
 d. Precision: it means how precise our method 
  is, and can we get the same result upon 
  repeating. It is achieved by testing same 
  sample numerous times at different days 
  by different individual under the same 
  operating conditions. It is performed to 
  determine intra-run assay and inter-run assay 
  variation. Precision can be determined by: 
   Precision= No. of repeated results in 
   agreement/ total no. of results x 100
 e. Specificity:  it is the ability of method to 
  detect only the analyte of interest in the 
  presence of other factors “Specificity” can 
  be defined as the ability of the method to 
  specifically separate the particular analyte in 
  the presence of other components.
   Specificity= No. of true negative results/ 
   (No. of true negative results + No. of 
   false positive results) x 100
 f. Sensitivity: it is the ability of method to 
  detect smallest quantity of analyte. 
  Selectivity refers to the ability of the method 
  to discriminate a particular analyte in a 
  complex mixture without interference from 
  other components
   Sensitivity: No. of true positive results / 
   (No. of true positive results + No. of 
   false negative results) x 100
 g. Positive predictive value: it is performed to 
  check the probability that a patient with a 
  positive test result has the disease or the 
  presence of an analyte in a specimen
   PPV=No. of true positive results / (No. 
   of true positive results + No. of false 
   positive results) x 100
 h. Negative predictive value: it is performed 
  to check the probability that a patient with a 
  negative test result does not have the disease 
  or the absence of an analyte in a specimen.
   NPV=No. of true negative results / 
   (No. of true negative results + No. of 
   false negative results) x 100
 2. Quality Control-(Performance and documentation)
  Kit’s commercial controls and internal 
  controls must be checked daily along with 
  the patients’ samples.
  Results should be documented in designated 
  forms and must be reviewed periodically 
  (daily by bench in-charge and monthly by 
  laboratory manager/consultant). 
  In case of erroneous quality control results, 
  patient sample results must be held back 
  and the cause evaluated. Repeat the tests by 
  alternative kit (same manufacturer and 
  same lot or same manufacturer with alternate 
  lot if available). If problem persists, 
  promptly coordinate with senior laboratory 
  management.  
 3. Equipment maintenance:
  Equipment maintenance is scheduled as 
  daily, weekly, biannually or annually. 
  This schedule must be defined and 
  documented for all instruments and 
  coordinate with the defined protocols 
  and the designated person who will perform 
  that maintenance activity.  
  Equipment maintenance include daily 
  cleaning of instrument, calibration (if 
  required) before initiating to run the clinical 
  sample. If there is any error or nonfunctional 
  instrument or component, coordinate with 
  biomedical department or inform laboratory 
  manager if instrument is in warranty period.
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 4. Lot-to-Lot verification :
  Whenever new lot of any kit is received 
  it must be verified before performing on 
  patient’s sample.
  Post-analytical:
 1. Review of results:
  All results are reviewed by consultant before 
  reporting to the patient
 2. Audits:
  Internal and external audits are performed at 
  different interval to ensure compliance with 
  national and international guidelines.
 3. Reference ranges: In case of quantitative 
  tests, reference ranges must be provided on 
  patient’s final report so that it can be helpful 
  for the treating physicians to interpret the 
  result cautiously. 
Quality Assurance ensures systematic monitoring 
and evaluation of the various aspects of a project, 
service, or facility to ensure that standards of quality 
are being met. Maintaining Quality Standards in 
Antimicrobial susceptibility testing is an important 
tool to ensure that the results are being correctly 
delivered to the patients.
For maintaining Quality Assurance of a certain 
automated testing system, there are certain elements 
which must be kept in mind when drawing up an 
Individualized Quality Control Plan (IQCP). These 
key elements are Specimen, Reagent, Environment, 
Testing Personnel, and Test System. All issues to 
be monitored can easily be distributed under these 
parameters and can thus be monitored accordingly, 
with preventive actions in place, anticipating any 
errors. If anything new comes up, a tailored preventive 
action can be added to the IQCP under the above 
categories and monitored. Each anticipated problem 
can be given a risk grade according to the seriousness 
of the problem. The main elements of IQCP include 
Risk Assessment, Quality Control Plan and Quality 
Assessment. An IQCP for the entire process must 
address the failures and errors in Pre Analytic, 
Analytic and Post Analytic phases of testing.
Risk Assessment
Risk Assessment is based on five elements Specimen, 
Test system, reagent, environment and testing 
personnel, and laboratory must ensures that all these 
five parameters are covered in the Risk Assessment 
plan.
	 l Specimen quantity should be acceptable 
  according to the manufacturer’s instructions 
  otherwise inadequate quantity of specimen 
  can cause false positive results and can cause 
  kit reagents to perform improperly. Reagent 
  integrity and expiration date needs to be 
  checked before patient testing. Each lot 
  should be verified before setting up 
  susceptibilities, and reagents and kits 
  should be stored in scientific grade 
  refrigerator. QC is performed weekly to 
  monitor effect of transient temperature 
  fluctuations on the integrity of each analyte 
  and performance of each equipment.
	 l Instrument diagnostics for temperature and 
  optics fail which lead to frequent 
  terminations and error. Dust from uncovered 
  surfaces may interfere with the optics 
  causing power failures and affects 
  instrument. To prevent this, instrument 
  should be kept in areas with less dust fallout, 
  optics cleaned after frequent intervals and 
  regular instrument maintenance is required.
	 l Training of staff is also necessary because 
  if staff is not trained for setting up 
  susceptibilities, incorrect results will be 
  reported. Competency assessment and sign 
  off by trainer of all staff must be completed 
  before carrying out procedure on clinical 
  specimens. Adherence to Patient Safety   
Overcoming Challenges in Quality Assurance: 
Antimicrobial Susceptibility Testing by an 
Automated System 
Asima Shahid Sabzwari
Clinical Microbiology
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  Goal #1 deserves special mention 
  here; matching the Name and Laboratory 
  / Medical Registration Number is of 
  foremost importance as there is zero 
  tolerance for this error.
Quality Control Plan
The Quality control plan should have certain 
parameters that include:
	 l Error Detection: if an error occurs before 
  during or after testing it should be detected 
  immediately
	 l It should specify the number, type and 
  frequency of Quality control material to be 
  tested
	 l QC acceptable ranges should be defined
	 l QCs performed should be according to the 
  manufacturer’s instructions, no less
	 l Indicate that your laboratory director has 
  reviewed, signed and dated the QC plan 
  document
Quality Assessment
Quality assessment can be monitored by considering 
following aspects:
	 l There should be a record of Temperature 
  logs for room temperature, refrigerator and 
  freezer to ensure that temperature is being 
  monitored on daily basis. Instrument ambient 
  temperature can be affected if there is failure 
  of engineering controls over air conditioning 
  so this should be monitored by engineering 
  department servicing lab. Since the test 
  results are accepted as long as the QC 
  remains within the acceptable range, 
  ensuring the quality and integrity of the QC 
  material is supreme for the analytic phase. 
	 l If Quality control fails, results on patient 
  samples are unacceptable or unreportable 
  if no obvious cause is found. This can 
  happen if Quality control ATCC strains 
  are not pure, too old or too young QC 
  cultures are used (correct age is 24-hour old 
  colonies), incorrect control strains are used 
  for the test, or inappropriate media is used 
  for revival of QC strains. To avoid such type 
  of errors, ATCC strains are revived weekly 
  according to a standard ATCC maintenance 
  plan, and all strains are saved at -80  
  degrees Celsius in a separate freezer box to 
  ensure conservation of their genotype/
  phenotype.
	 l Quality control log should also be   
  maintained and reviewed regularly to 
  ensure that corrective action has been taken 
  for any unacceptable values
	 l Manufacturer’s instructions should be 
  reviewed with each new lot or shipment and 
  if there is any change it should be updated in 
  the policy
	 l Review of Personnel competency records 
  should also be done
Quality Assurance can be maintained by 
following all the standards stated above. Our 
experience with the IQCP for automated AST 
(Vitek 2 system) has so far been very useful 
in ensuring correct reporting of results. Any 
inconsistencies or errors are analysed and if 
necessary, the IQCP is revised to include new 
occurrences or reduce the risk level of previously 
addressed issues. We have been following all 
these standards and performing quality control on 
weekly instead of daily basis since almost 2 years 
and are able to report automated susceptibilities 
with confidence.
A 14 year old boy presented with progressive pain 
in right leg, which was more at nights, and relieved 
by taking non-steroidal anti-inflammatory drugs 
(NSAIDs). A plain x-ray was performed followed by 
computerized tomography (CT) scan. The CT scan 
showed a radiolucent nidus surrounded by sclerotic 
bone (Figure 1A,B). Resection of the nidus with 
surrounding bone was done. 
Radiology Pathology Correlation
Dr Nasir Ud Din and Dr Dawar Khan
Histopathology and Radiology
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Histopathologically, the nidus was composed of 
multiple fragments of haphazardly interanastomosing 
trabeculae of variably mineralized woven bone with 
osteoblastic rimming. The intertrabecular stroma is 
fibrovascular (Figure 2A,B). The surrounding bone 
was thick sclerotic. A diagnosis of osteoid osteoma 
was made based on radiological and histological 
features correlation.
Osteoid osteoma is a benign bone forming 
lesion most frequently seen in children and 
young adults and has a peak incidence in 
the second decade of life. There is a male 
predilection. The tumor most commonly 
involves long bones of distal extremities, 
particularly femur neck.
Clinically, the most common presentation is 
pain of several months’ duration seen is 80 
percent of patients. The pain is intermittent 
at first, then becomes relentless and is more 
severe at night. Aspirin and other NSAIDs 
are very effective in alleviating the pain for 
several hours at a time. The pain is believed to 
be elicited by high levels of prostaglandin E2 
and prostacyclin found within the nidus. 
Radiological differential diagnosis of 
osteoid osteoma is osteoblastoma, brodie’s 
abscess, cortical stress fracture, and bone 
island. Histologically, the closest differential 
diagnosis is osteoblastoma. The characteristic 
pattern of nocturnal pain in osteoid osteoma 
is not seen in osteoblastoma and these tumors 
preferentially involve the axial skeleton. 
The diagnosis of the two tumors is made by 
correlating overall clinical, radiological, 
and histopathologic features. In borderline 
cases, an arbitrary size cutoff of 1.5 cm has 
historically been used.
Figure 1A, B. CT coronal and axial images shows focal cortical thicken-
ing along a small lytic area and a nidus in proximal tibia.
A B
Figure 2A, B. Histological examination of osteoid osteoma nidus shows 
interconnecting trabeculae of woven bone with fibrovascular stroma
A B
Proficiency testing (PT) is the external component 
of quality control since it involves peer review. 
It primarily measures accuracy because each 
laboratory’s results are compared to the interlaboratory 
or peer group mean, which is assumed to be the true 
value. The graphs in PT evaluation reports can be 
helpful in identifying problems even before PT results 
become unacceptable or before incorrect patient 
results are released.
Utilizing SDI for diagnostic interpretation of PT 
survey report 
Proficiency test results are reported as standard 
deviation indexes (SDIs). This index represents 
the number of standard deviations each result is 
from the peer group mean. The SDI is calculated 
by the following formula: SDI = (your result - 
interlaboratory mean)/ interlaboratory SD. The 
Identifying Problems before Proficiency 
Testing Fails
Dr Lena Jafri
Clinical Chemistry
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best way to detect problems is to examine these 
SDI results critically in PT evaluation reports. The 
following rules are useful in evaluating SDI results:
	 l Do two or more of the five SDI results 
  exceed +/- 1? If not, a significant error is 
  unlikely and evaluation is complete.  If so, 
  further questions need to be asked.
	 l Atleast one result exceeds +/- two SDI: 
  review results to rule out possible problems, 
  identify possible errors from non-analytical 
  sources for results with very high SDIs.
	 l The average of the five SDI results is more 
  than +/- 1.5: indicates significant bias 
  (systematic error) , calibration data should 
  be reviewed to determine if a shift has 
  occurred. Bias can usually be eliminated by 
  recalibration.
	 l One PT result is more than +/- three SDI : 
  there is a high probability of random error.
	 l The range of SDI between the largest and 
  smallest PT result exceed 4 SDI:  random 
  error is a possibility and the procedure 
  should be evaluated for potential sources of 
  imprecision.
Allowed Deviation and Patterns in PT Evaluation 
Graphs 
The PT evaluation report also includes graphical 
summary using the relative distance of your results 
from the target. This distance is called the allowed 
deviation. Allowed deviation is calculated by 
subtracting the target value from your laboratory 
result and dividing this difference by the PT 
allowable error for that analyte. The ratio is then 
multiplied by 100 to bring the value on a percent 
scale ranging from -100 to +100. If results are 
beyond -100 to 100 ‘x’ appears on the report 
indicating that results exceed the graphical limit. 
Monitoring PT graphs and rules using allowed 
deviation has also been useful in identifying 
problems before PT fails.
Patterns in PT Graphs for a Single Mailing/ Single Survey:
	 l One result in a mailing exceeds +/- 75 
  percent of the allowed deviation: review 
  results to rule out possible problems, identify 
  possible problems from non analytical 
  sources such as clerical errors for results that 
  exceed +/- 100% of the allowed deviation.
	 l All results are on one side of the target 
  values with atleast one difference exceeding 
  +/- 50 percent of the allowed deviation: 
  shows bias indicating a possible calibration drift .
	 l Large positive and negative differences; 
  combined lengths of longest positive and 
  negative bars is >140 out of total range of 
  200: depicts random error
Patterns in PT Graphs over Multiple Mailings:
	 l Persistent results on one side of the target 
  values: shows persistent bias, even if small, 
  recalibration should have occurred within 
  this time frame.
	 l Results flip from one side of target to the 
  other (Figure 1): shows impact of system or 
  process changes, longer bars are of more 
  concern. Follow suggested action for 
  systematic errors.
	 l Over time, length of bars increase (Figure 2): 
  a sudden shift may show impact of system 
  or process changes, most likely random 
  error,  may reveal new source of either 
  systematic or random error.
	 l Over time length of bars increases primarily 
  on one side (Figure 3): depict persistent bias, 
  take corrective action for systematic error.
	 l Over time, length of bars decreases: shows 
  impact of system or process changes, 
  particularly as a result of corrective action.
Sometimes by reviewing results from multiple PT 
mailings or surveys, performance trends that could 
lead to PT failures are easily recognized and rectified. 
For example graphical plots by College of American 
Pathologists PT evaluation reports can identify trends 
that would be missed without reviewing multiple PT 
events together. As discussed above reviewing PT 
results carefully over time can identify persistent bias, 
trends, and shifts, change in system and/or process, 
systematic error, evidence of corrective action, 
training opportunities and staff competencies.
C-C
C-B
C-A -100  -80  -60  -40  -20  0  20  40  60  80  100
Figure 1: Results flip from negative to positive bias.
Figure 2: Lengths of bars increase over time on both sides.
Figure 3: Lengths of bars increase over time on one side of target mean.
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The haemoglobin molecule within red blood cells is 
essential for transporting oxygen to the tissues along 
with carbon dioxide removal and buffering action 
to maintain pH within red cell. Adult haemoglobin 
is a 64.4 kDa hetero tetramer comprising of iron-
containing porphyrin called haem and two pairs of 
globin polypeptide chains that includes one pair of 
alpha and one pair of non-alpha chains. In adults, 
96-98 percent haemoglobin A (α2β2) and 2–3.5 
percent of haemoglobin A2 (α2δ2) are present. Sickle 
haemoglobin (Hb S) is a variant haemoglobin that 
results from valine for glutamic acid substitution 
at position 6 of β globin chain. Homozygosity for 
haemoglobin S (βSβS) causes a serious condition 
referred to as ‘sickle cell anemia’. Heterozygosity 
for haemoglobin S (ββS), referred to as sickle cell 
trait, is usually asymptomatic. The βS gene may also 
be co-inherited with another β chain globin variant 
e.g. sickle beta thalassaemia. On deoxygenation 
and dehydration, HbS solubility is reduced and 
irreversible polymerization occurs, causing vascular 
obstruction. This phenomenon in vivo has deleterious 
effects such as hand–foot syndrome, acute chest 
syndrome, cerebral haemorrhage or infarction, 
priapism, acute pain crisis, splenic crisis, recurrent 
infections and others.
Various diagnostic methods for identification of HbS 
include haemoglobin electrophoresis at alkaline and 
acidic pH, isoelectric focusing and high performance 
liquid chromatography (HPLC). HPLC is one of 
the widely utilized methods for HbS detection.  On 
HPLC, HbS elutes at retention time of 4.5 minutes 
(4.30–4.70 minutes) however, a number of other variant 
haemoglobins also co-elute at the same retention 
time such as Hb Q-Thailand (Mahidol), HbA2´, Hb 
Manitoba, HbE- Saskatoon, Hb Montgomery and others. 
Therefore, it is essential to identify HbS accurately 
in order to differentiate it from other haemoglobins 
for proper patient diagnosis and future counseling. 
Laboratory accrediting bodies such as College of 
American Pathologists (CAP) recommends that if a 
patient sample appears to have Hb S in the primary 
screening; the laboratory should perform a second 
procedure to confirm the presence of Hb S.  In order to 
fulfill this quality requirement, section of haematology 
and transfusion medicine at Aga Khan University 
performs sickling test on every patient sample that have 
variant haemoglobin in S-window on HPLC. In this test, 
patient’s sample is combined with Sodium Metbisulfite 
as a reducing agent which causes red cell deoxygenation. 
If HbS is present, red cells lose their smooth round 
shape and become sickle shaped. The presence of sickle 
shaped cells is confirmed by examining the slide under 
microscope along with review of both positive and 
negative control samples. Very rarely when sickling test 
is also negative, we advise patient to confirm presence of 
sickle cell disease by molecular testing.
In this way, identification of HbS is confirmed 
by two 
different 
methods and 
accurate report 
is provided to 
patients. Thus, 
patient safety 
and appropriate 
future 
management in 
ensured.
Quality Requirements for Reporting Sickle 
Haemoglobin
Dr Nazish Sana and Dr Muhammad Shariq Shaikh
Haematology & Transfusion Medicine
Patient with Sickle cell trait: A, Leishman stain at 40x showing absence of sickle cells. B, Chromatogram showing variant haemoglobin in S-window. 
C, Sodium metbisulfite preparation showing sickling RBCs
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Bronchoscopes are medical devices widely used 
for diagnostic and therapeutic procedures in a 
different variety of patient populations. Flexible 
bronchoscopes are critical equipment as they are 
introduced in sterile body cavities and should be 
decontaminated after each procedure to eliminate 
all forms of microbiological life, including 
bacterial spores. Appropriate reprocessing of 
flexible bronchoscopes is a multistep procedure 
involving washing followed by sterilization 
or high-level disinfection with further rinsing 
and drying before storage.  Proper storage is 
obligatory. However adequate decontamination 
of bronchoscopes is laborious and often 
ignored to save resources, time and workload 
which has serious implications on patients’ 
health and can result in bronchoscopy-related 
healthcare associated infections, outbreaks and 
psuedooutbreaks. 
Mycobacterium Tuberculosis, non-tuberculous 
mycobacteria (NTM), and Pseudomonas 
aeruginosa are the most common pathogens 
associated with transmission during bronchoscopy. 
Quality Assurance of Bronchoscopically 
Collected Samples
Tazeen Fatima 
Resident Clinical Microbiology
Inadequate cleaning, disinfection, surface wiping and channel 
flushing, use of inadequate detergent/disinfectant (expired, low 
potency, resistance of microorganisms)
Use of damaged and leaking scopes and re-use without 
decontamination
Improper storage (the scopes must hang down straight), and 
inadequate infection control practices and hand hygiene
Contamination Sources
All images courtesy Google images
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Bronchoscopically transmitted infections have grave 
consequences on patients’ health and associated 
with enormous healthcare costs as positive cases are 
often investigated with repeat cultures and advanced 
radiological investigations to rule out false positivity. 
Those patients are bound to receive unnecessary 
antimicrobials until and unless contamination has 
been ruled out and also bear adverse effects of 
unnecessary treatment. Contaminated bronchoscopy 
respiratory samples are a huge burden from 
laboratory diagnostic point of view as it requires 
extensive laboratory work, increased uses of 
resources, manpower and time consumption.
Bronchoscopy related infectious complications 
reported are rare but the incidence is probably 
underestimated, with many episodes unrecognized 
and uninformed. Failure of adequate cleaning and 
disinfection procedures is the major cause and can 
be avoided by proper disinfection/ sterilization, 
adequate reprocessing of bronchoscopes and 
stringent infection control practices.
Potential Sources of Error in Report
Preanylytical
1. Exogenous infectious material 
 introduced in patient could lead to 
 bronchoscopically transmitted 
 infections (increased morbidity and 
 healthcare cost!)
2. Collection of poorly representative 
 and contaminated sample of BAL 
 (Garbage in garbage out!)
Analytical
1. Heavily contaminated samples 
 (Possibility of missing out true 
 pathogens!)
2. Extensive laborious and strenuous 
 laboratory work (ensuring presence 
 of true pathogens, identifying pseudo 
 outbreaks and investigating true 
 outbreaks)
3. Increased cost and logistic burden on 
 labs
Postanalytical
1. Delay in reporting/ communication to 
 physician from laboratory
2. Commencement of unwarranted 
 treatment to patient in case of over 
 reporting
Flow cytometry is a dynamic technology which 
together with specific antibody and fluorochrome 
reagents allows to preview at the surface, 
cytoplasm and DNA content of thousands of 
cells suspended in fluid. It is particularly useful 
to determine lineage and potential biologic 
behavior of targeted cells. The key feature of this 
technology is the use of monoclonal antibodies in 
order to ensure epitope specificity. Today, these 
antibodies are available from several commercial 
suppliers for utilization in diagnostic assays. 
These antibodies must go through stringent QC 
during manufacturing, distribution, evaluation and 
utilization in testing patient samples. 
Besides general handling of reagents such as 
storage conditions, expiration dates, and “in-
use” status, several other factors unique to flow 
cytometry reagents are critical in efficient antigen-
antibody reactions. These factors include: the 
quality of the sample, the viability of cells, the pH 
of the environment, and the amount of antigen and 
antibody available for reaction. 
The foremost requirement is validation of 
reactivity of each fluorescent-conjugated antibody 
before its intended use. The optimal concentration 
at which antigen-positive cells can be best 
distinguished from nonspecific binding on antigen-
negative cells should be determined. For instance, 
over-expression is an increased number of antigens 
per cell and is observed in certain hematological 
malignancies. In contrast, weak or dim reactivity 
may result from decreased concentration of 
antibodies leading to misinterpretation of 
results. To resolve this, titration experiments are 
performed with variable dilutions. The data is then 
analyzed for signal to noise ratio, percentages of 
stained and unstained cells and intensity of the 
stain.
Antibody and Reagent QC for Flow 
Cytometry Assays
Dr Muhammad Shariq Shaikh and Dr Arsalan Ahmed
Haematology and Histopathology
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What is method validation? According to Clinical 
& Laboratory Standards Institute (CLSI), 
validation is ‘‘The process of testing a measurement 
procedure to assess its performance and to determine 
whether that performance is acceptable.” The 
six elements of method validation are: precision, 
accuracy, reportable range verification, reference 
intervals establishment or verification, sensitivity* 
and specificity* (*for non FDA approved or 
laboratory modified assays). Following table shows 
the protocol to be followed in validating a new test 
and it should be documented.
Method Validation: College of American 
Pathologists (CAP) requirements of Method 
Validation of Quantitative Tests in a Clinical 
Laboratory
Dr. Sibtain Ahmed 
Chemical Pathology
Elements
Precision
Precision indicates 
repeatability, which means, 
analyze repeatedly to 
determine variation.
Accuracy
Closeness of the agreement 
between test result and 
‘‘true’’ result.
Reportable Range
Analytical Measurement 
Range (AMR)
Clinically Reportable Range 
(CRR) 
Reference Intervals
How it is Done
To verify inter-assay variation, samples should be processed twice a day in quadruplicate for 5 
days producing 20 readings.  For intra-assay variation, one sample is run 20 times. Imprecision is 
quantified by calculating the mean, standard deviation (SD), and coefficient of variation (CV %) of 
data collected from an analytical run
Two Approaches : 1. Comparison of results between new method and ‘‘reference’’ method. 2. 
Results using new method on certified reference materials or controls.
The first approach is most commonly used. For this run 20 samples within testing range (CLSI 
document EP15-A2) by both new and comparative methods. Results are acceptable if the average 
bias between the two methods is within allowable limits.
AMR (Range of analyte values that a method can directly measure on the specimen, without 
any dilution, or other pretreatment) verification must include three levels—low, midpoint, high. 
One can use commercial linearity materials, proficiency testing (PT) samples, controls or patient 
samples with known results, standards or calibrators. It can also be done by calibration verification, 
if three samples that span the measurement range are used. CRR (range of analyte values that are 
reported as a quantitative result, allowing for specimen dilution or other pretreatment)  is a clinical 
decision by the laboratory director/section heads, and does not require experiments or re-validation; 
however, dilution or concentration protocols must be specified in methods
It is not mandatory but preferable for a laboratory to establish its own reference limit. One can 
adopt reference limits from any of the following sources: manufacturer suggested, reference 
laboratory, published articles, neighboring laboratory or previous reference limits in the same 
laboratory. However reference interval verification is essential for standardized routine analytes.  
For verifying reference intervals, we should select 20 representative healthy individuals, and the 
test will considered validated if, ≤ 2 of them is outside the manufacturer’s proposed limit. If > 2 
outside, can repeat with another 20, and accept if ≤ 2 is outside.
Additionally, to verify acceptable performance, 
all new lots of reagents used in laboratory testing 
must be verified against old lots. This includes all 
the reagents whether prepared in the laboratory 
or purchased from suppliers such as buffers and 
lysing reagents. A positive patient sample can 
be run concomitantly with the new and old lot 
of reagent. Depending on the use of reagents, 
acceptability criteria should be established and 
achieved results should be documented. 
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This year International 
Federation of Clinical 
Chemistry (IFCC) organized 
two events at Durban South 
Africa: XIVth International 
Congress of Paediatric 
Laboratory Medicine (ICPLM) 
and International Congress 
of Clinical Chemistry and 
Laboratory Medicine, Worldlab. 
The ICPLM was organized by 
the Task Force on Paediatric 
Laboratory Medicine (TF-
PLM) in cooperation with the 
African Federation of Clinical 
Chemistry (AFCC), on 20-21st 
October 2017. International 
Congress of Clinical Chemistry and Laboratory 
Medicine, Worldlab was organized in partnership 
with South African Association for Clinical 
Biochemistry (SAACB) and AFCC, from October 
22nd to 25th 2017.
One of the goals of the IFCC is to identify and 
nurture talented young scientists and increase 
participation of pathologists from developing 
countries. The IFCC achieves this goal by 
giving travel grants to its member societies 
from different countries. This year Dr Hafsa 
Majid and Dr Sibtain Ahmed were awarded 
these scholarships from Pakistan. Dr Sibtain 
Ahmed also received 2nd best prize for poster 
presentation on abstract regarding neonatal 
TSH reference interval in Pakistan. In both 
conferences high quality scientific programs 
were arranged. The plenary sessions covered 
wide range of topics ranging from innovations 
in techniques, neonatal and newborn screening, 
evidence based laboratory medicine, laboratory 
accreditation, incidence and spectrum of inherited 
metabolic diseases in South Africa, application 
of big data, standardization, reference intervals 
establishment and risk management. 
The conference attracted people from many 
countries and continents and provided an eclectic 
mix of topics relevant to Clinical Chemistry 
including practical overview of latest advances 
in the field of laboratory medicine. To conclude, 
this was an overwhelming and rewarding 
experience. 
Meeting Report of International Federation of 
Clinical Chemistry (IFCC) Conferences- 2017
Reported by Dr Sibtain Ahmed and Dr Hafsa Majid
Clinical Chemistry
Figure 1: Participants from Pakistan at ICPLM & IFCC-Worldlab 2017
hospitals.aku.edu/Karachi/clinical-laboratories
